Toronto, Canada – November 18, 2025 — Visionary Holdings Inc. (“GV” or the “Company”) (Nasdaq: GV), a technology-driven multinational enterprise, today released a Letter to Shareholders from Chief Executive Officer Xiyong Hou, detailing the Company’s strategic transformation, accomplishments in regenerative medicine, and long-term roadmap for capturing opportunities in the rapidly expanding global longevity economy.

Letter to Shareholders from CEO Xiyong Hou

Dear Fellow Shareholders,

I hope this message finds you well. I am writing to share an update on GV’s strategic progress, our expanding business initiatives, and the clear roadmap that will guide the Company’s next stage of development. Over the past year, GV has undergone a meaningful transformation that is reshaping our industry positioning and growth trajectory, laying a strong foundation for our long-term competitiveness.

GV is transitioning from a traditional education technology company into a global regenerative medicine and longevity technology enterprise. This strategic shift is driven by profound global trends—rapid population aging, the rising incidence of chronic diseases, and the growing demand among consumers to extend healthy lifespan. Regenerative medicine, cellular rejuvenation, AI-driven health management, and premium medical consumption are forming one of the fastest-growing markets worldwide, with opportunities measured in the tens of billions to trillions of dollars. We believe GV is well-positioned to participate meaningfully in this generational shift.

Over the past year, we have successfully completed several key initiatives in this direction. GV has established a deep strategic partnership with Jiangsu Yike Regenerative Medicine (“Yike”), one of China’s leading regenerative medicine research institutions. Through a series of milestone agreements signed in 2025, GV secured the global rights to Yike’s breakthrough stem cell technologies, including its core stem cell therapy for both Type 1 and Type 2 diabetes, which has demonstrated promising potential in achieving long-term remission and even possible cure in clinical applications. In addition, Yike’s Nano-Delivery™ smart transdermal system, AI-based aging assessment model, and platforms for telomerase homeostasis and immune cell technologies are now integrated into GV’s global technology framework.

These technologies represent some of the most advanced capabilities in the field and provide GV with a differentiated combination of scientific depth and global commercialization potential.

We have also accelerated commercialization efforts. In November 2025, GV’s Asia-Pacific headquarters in Hong Kong officially launched a medical-grade anti-aging product portfolio, encompassing stem cell rejuvenation therapies, NK cell revitalization, precision cellular repair programs, and personalized longevity management services. These products have been introduced across mainland China, Hong Kong, and Singapore. Asia’s premium regenerative medicine and medical aesthetics market surpassed USD 28 billion in 2023 and is projected to more than double by 2030. We believe this launch represents an important milestone for GV and will become a key revenue driver in the coming fiscal years.

At the same time, GV is advancing its North American expansion. We have initiated exploratory cooperation to establish North America’s most advanced AI-driven Anti-Aging and Health Center at our downtown Toronto property. This center aims to integrate AI-powered diagnostics, regenerative medicine technologies, personalized medical interventions, and collaboration with leading North American medical institutions. The combination of Asian commercial scalability and North American clinical credibility will enable GV to build a global dual-center longevity platform, elevating our global presence and long-term competitiveness.

Looking ahead to the next three years, GV’s strategic path is clearly defined: secure world-class regenerative technologies, accelerate commercialization, build international research and clinical validation capabilities, and establish a global network spanning Asia and North America. Guided by science and driven by execution, GV will continue to strengthen its business fundamentals and long-term market value.

We understand the importance of the trust our shareholders place in us. GV’s transformation is not a short-term initiative, but a forward-looking, multi-year strategy designed to build lasting competitive advantages. As our regenerative medicine and longevity businesses scale, we are confident the capital markets will increasingly recognize GV’s intrinsic value and long-term potential.

Thank you for your continued support. We remain committed to transparency, disciplined execution, and high standards of governance, and we will continue to keep you informed as we achieve key milestones.

Sincerely,
Xiyong Hou
Chief Executive Officer
Visionary Holdings Inc. (Nasdaq: GV)

---

About Visionary Holdings Inc.
Visionary Holdings Inc. (Nasdaq: GV) is a technology-driven multinational enterprise focused on innovative education, AI applications, and high-tech healthcare solutions. Headquartered in Toronto, Canada, the Company operates through its subsidiaries across North America and Asia, driving technological advancement, cross-border innovation, and global health transformation.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934 and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will”, “expects”, “anticipates”, “future”, “intends”, “plans”, “believes”, “estimates”, “target”, “going forward”, “outlook,” “objective” and similar terms. Such statements are based upon management’s current expectations and current market and operating conditions, and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and which are beyond GV’s control, which may cause GV’s actual results, performance or achievements (including the RMB/USD value of its anticipated benefit to GV as described herein) to differ materially and in an adverse manner from anticipated results contained or implied in the forward-looking statements. Further information regarding these and other risks, uncertainties or factors is included in GV’s filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov. GV does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under law.

Contacts:

Visionary Holdings Inc.

Investor Relations
Email: [email protected]